Urinary interleukin-4 levels in nephrotic children with and without concomitant asthma.

Amal A Al-Eisa, Maysoun Al-Rushood
Associate Professor, Department of Pediatrics, Faculty of Medicine, Kuwait University, Kuwait.

Abstract

Background and Aim: The role of cytokines in the immune-pathogenesis of idiopathic nephrotic Syndrome (INS) had been widely postulated. Some cytokines, most importantly IL-4, have been also involved in the pathogenesis of asthma. The majority of INS patients do exhibit a form of atopy including asthma, implying a common pathological background of both diseases. The aim of this study is to explore the role of IL-4 in the pathogenesis of a relapses in INS patients with Asthma compared to those without concomitant asthma.

Patients and Methods: Demographic, biochemical data and mean urinary IL-4 levels were evaluated in 41 steroid-sensitive INS patients and 30 matched Asthmatic controls without INS or atopy. Mean urinary IL-4 levels in INS patients were compared to controls as well as in the 2 subgroups of INS patients: Group A (INS with Asthma, n=14) and Group B (INS patients without Asthma or atopy, n=27) to controls during relapse and remission.

Results: Mean age of patients at study was 8.9 ± 3.5 years (range: 49 months-15 years). Male: Female ratio was 28:13. Mean serum creatinine was 49 ± 10 µmol/l and mean serum albumin was 29 ± 10 g/l. Mean urinary IL-4/Cr in INS patients during relapse and remission was 12.170 ± 20.013 pg/µmol and 15.269 ± 41.275 pg/µmol, respectively (P=0.716). Both levels were not statistically different when compared to controls (24.78 ± 89.51 pg/µmol) (P=0.5431 and P=0.662, respectively). Mean urinary IL-4/Cr level was significantly higher in Group A vs. Group B during relapse (28.22 ± 26.12 pg/µmol vs. 2.73= ± 3.38 pg/µmol, P=0.003) and during remission (31.52 ± 57.13 pg/µmol vs. 1.04 ± 1.48 pg/µmol, P=0.004). Group A patients had a higher mean urinary protein excretion and a longer duration to remission than group B patients.

Conclusion: INS patients with asthma have a higher IL-4 excretion which might increase the severity and duration of proteinuria. The coexistence of Asthma in INS patients requires an early and abrupt treatment of relapses.

Keywords: Idiopathic nephrotic syndrome (INS), Bronchial asthma, Interleukin 4 (IL-4), Relapse, Remission.
regarding the serum levels of IL-4 in INS patients and no previous studies correlated urinary IL-4 levels in INS during relapse and remission. Moreover, data on the effect of coexistence of Asthma with INS on the clinical pattern and course of the disease are lacking in the literature.

In this study we investigate the levels of urinary excretion of IL-4 in INS patients with and without Asthma exploring its role and possible effect on relapses of INS patients with and without asthma.

Patients and Methods

Children aged 1-12 years who were diagnosed with steroid-sensitive idiopathic nephrotic syndrome during the period January 2012 to December 2015 were recruited in the study. All were managed in the outpatient clinics of the department of Pediatrics at Mubarak university teaching hospital. All patients were either newly-diagnosed at their first presentation or known to have INS but were off steroids treatment for more than 2 months prior to inclusion. All patients were treated for their relapse with the standard daily dose of prednisolone (60 mg/M²/day).

Patients (newly-diagnosed or the known INS) who did not show response to steroid within 4 weeks were excluded from the study. Previously diagnosed-INS patients who had a non-minimal change histopathology or had received second or third line immunosuppressive treatment within 6 months prior to the study were also excluded. Fourteen of included INS patients had a confirmed diagnosis of atopic bronchial asthma for more than 6 months with no other atopic symptoms. All had a well-controlled asthma for more than 2 months prior to inclusion and were not on long-term prophylactic medications or on steroid inhalers. The other 27 INS patients had no atopic history or asthma. Asthma was defined, as per American Academy of Allergy Asthma and Immunology (AAAI) as a chronic inflammatory condition of the airways characterized by 3 features including airway obstruction that is at least partially reversible by bronchodilators, airway hypersensitivity or hyper-responsiveness to a variety of external stimuli and chronic inflammation of the airways [14]. Atopy was defined as the genetic tendency to develop allergic diseases such as allergic rhinitis, asthma and atopic dermatitis which is associated with heightened immune responses to common allergens such as inhaled or food allergens [14]. Diagnosis of asthma and atopy were confirmed by expert allergists who examined all Asthmatic patients as well as controls. Diagnosis of INS was based on the presence of edema, nephrotic-range proteinuria and hypoalbuminemia [15,16]. Nephrotic-range proteinuria was defined as the presence of ≥ 40 mg/M² body surface area/h or a Protein: Creatinine ratio on early morning urine of ≥2.0. Hypoalbuminemia was defined as a serum albumin level <25 g/L. Relapse of nephrotic syndrome was defined as the appearance of nephrotic range proteinuria or urine albumin dipstick of ≥2+ on 3 successive days. Remission was defined as disappearance or trace of proteinuria on albumin dipsticks for 3 successive days.

Thirty Asthmatic age and sex-matched children of the same ethnic background were included as controls and were evaluated by an experienced allergist to confirm the diagnosis of Asthma, the absence of other atopy or proteinuria. All controls had a well-controlled asthma with no exacerbations for more than 2 months prior to inclusion and were not on long-term prophylactic medications nor on steroid inhalers. All controls had a serum creatinine (within 15-80 µmol/l) and normal serum albumin level (Range: 30-40 g/l).

Urinary samples for IL-4 were collected from INS patients (both group A and group B) at presentation with a relapse before the initiation of prednisolone therapy. A second sample was collected at day 7 of attaining a remission. All controls had their urinary IL-4 level at their visit to the clinic and after confirming their fulfillment of the inclusion criteria as controls.

Cytokines Assay

Freshly voided urine samples were collected and centrifuged at 1500×g at 40°C for 20 min. The supernatant was then collected, aliquoted and immediately frozen at -80°C until assessment. ELISA assay for IL-4 was carried out using commercial kits purchased from Biosource International (San Diego-California-USA). The minimum detection range of IL-4 cytokine was 20.8 pg/ml. Immunoassays for the quantitation of cytokine by Flowcytomix kits (Bender Medsystems GmbH, Vienna, Austria), according to manufacturer’s instructions.

Statistical Analysis

Statistical analysis and graphical presentation was performed using SPSS 22 on P.C. Mann-Whitney nonparametric test was used to compare the significant difference in the values between the groups. X² or Fisher’s exact test was applied to evaluate differences in proportions. All p-values are two-sided and p<0.05 indicates the statistical significance.

Results

A total of 41 patients with INS were included. The mean age of patients at study was 8.9 ± 3.5 years (range: 49 months-15 years). They were 28 male and 13 female. A total of 14 INS patients had definite history of Asthma as per AAAI criteria (group A) while 27 had no Asthma or atopy (group B). Newly-diagnosed INS patients were 21 whereas the other 20 patients were frequent relapsers who had a new relapse while off any immunosuppressive drugs as per inclusion criteria. A total of 11 patients received cyclophosphamide and 8 had cyclosporine during the course of their disease but were off these drugs for more than 6 months prior to recruitment. All INS patients had normal serum creatinine with a mean of 49 ± 10 µmol/l and Mean serum albumin level during relapse was 20 ± 4 g/l. Table 1 summarizes the clinical and biochemical data of patients and controls.
**Table 1. Clinical and laboratory data of patients with idiopathic nephrotic syndrome (INS) and controls at time of inclusion**

<table>
<thead>
<tr>
<th></th>
<th>INS Patients (n=41)</th>
<th>Controls (n=30)</th>
<th>Normal Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean Age (years)</td>
<td>8.9 ± 3.5</td>
<td>7.1 ± 2.3</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Male 28</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female 13</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Mean Serum Creatinine (µmol/L)</td>
<td>49 ± 10</td>
<td>54 ± 9</td>
<td>(15-88)</td>
</tr>
<tr>
<td>Mean Serum Protein (g/L)</td>
<td>50 ± 5</td>
<td>75 ± 3</td>
<td>(68-80)</td>
</tr>
<tr>
<td>Mean Serum Albumin (g/L)</td>
<td>20 ± 4</td>
<td>35 ± 3</td>
<td>(30-40)</td>
</tr>
<tr>
<td>Mean Serum Cholesterol (mmol/L)</td>
<td>6.3 ± 0.7</td>
<td>3.1 ± 1.5</td>
<td>(3.1-5.2)</td>
</tr>
<tr>
<td>Mean UP: Cr ratio* (mg/mg)</td>
<td>2.7 ± 0.6</td>
<td>0.02 ± 0.04</td>
<td>(≤ 0.2)</td>
</tr>
</tbody>
</table>

*UP: Urine Protein; Cr: Creatinine

**Cytokines Measurement**

Mean urinary IL-4, corrected to urinary creatinine, in INS patients during relapse and remission was 12.17 ± 20.01 pg/µmol and 15.26 ± 41.27 pg/µmol, respectively (P=0.716). Both levels were not statistically different when compared to controls (24.78 ± 89.51 pg/µmol) (P=0.54 and P=0.66, respectively) (Figure 1).

Comparing mean urinary IL-4 levels in Asthmatic (Group A) to Non-Asthmatic INS patients (Group B), levels were significantly higher in group A compared to group B during INS relapse (28.22 ± 26.12 pg/µmol vs. 2.73 ± 3.38 pg/µmol, P=0.03) as well as during remission (31.52 ± 57.13 pg/µmol vs. 1.04 ± 1.48 pg/µmol, P=0.04).

No significant difference was found comparing mean IL-4 level in group A to controls during relapse as well as during remission (P=0.85 and P=0.76, respectively). Moreover, when comparing mean urinary IL-4 level in Group B to controls, levels were significantly lower in the former group during relapse both during relapse and remission (P=0.05 and P=0.04, respectively). Figure 2 illustrates these results.

Mean urinary protein: creatinine ratio was significantly higher during relapse in Group A (3.3 ± 0.2 mg/mg) compared to Group B (2.4 ± 0.3 mg/mg) (P<0.05). Mean duration from starting prednisolone treatment for relapse to remission was significantly longer in Group A patients (18 ± 4 days) compared to Group B patients (7 ± 3 days) (P<0.05).

**Discussion**

The association between idiopathic nephrotic syndrome and allergic phenomenon was reported decades ago as INS was triggered by allergic reactions to stings, poison ivy and pollen and food hypersensitivity [4,17-20]. Asthma and allergic dermatitis were found in about 34 to 63% of nephrotic syndrome patients [4,6,7]. Moreover, INS incidence was found to occur 3.3 folds greater in asthma cohort than non-Asthma cohorts [21].

IL-4 production by mast cells and Th2 is important in the pathophysiology of allergic diseases including asthma. In an allergic model, IL-4 was found to increase the vasculature permeability and to enhance anaphylaxis by increasing sensitivity to mediators such as platelets activating factor, histamine, serotonin and leukotrienes [22]. These effects induced by IL-4 are the key pathophysiological changes observed in Asthmatic attacks.

Studies on the role of IL-4 in nephrotic syndrome patients are conflicting. Levels of Th2-associated cytokines such as interleukin-4 and IL-13 were found to be elevated in the serum of relapsing nephrotic patients in some reports.
Urinary interleukin-4 levels in nephrotic children with and without concomitant asthma.

...to do simultaneous measurements of IL-4 in serum and urine, which could have added much value to this work.

Conclusion
In conclusion, INS patients with asthma have a higher IL-4 excretion which might be a factor in increasing the severity and duration of proteinuria. The coexistence of Asthma in INS patients requires an early and more aggressive treatment of INS relapses. Targeting IL-4 with anti-cytokine therapy might be a future therapeutic option in managing INS relapses in patients with concomitant asthma.

Acknowledgement
We would like to thank Mrs. Asiyah Ebrahim for her technical help.

Ethical Approval
This study was approved by the Joint Committee for Protection of Human Subjects in Research of the Faculty of Medicine and Ministry of Health, Kuwait. Informed consent was obtained from the study subjects and/or their care givers as per regulations of the Ethics Committees.

References

Correspondence to:
Amal A Al-Eisa,
Associate Professor,
Department of Pediatrics,
Faculty of Medicine,
Kuwait University
P.O. Box 23924, Safat 13110,
Kuwait City,
Kuwait.
Tel: 965-25319486
Fax: 965-25338940
E-mail: amal@hsc.edu.kw